TransCode Therapeutics announces 1-for-28 reverse stock split to regain Nasdaq compliance

Transcode Therapeutics, Inc.

Stockholders approved 1-for-28 reverse split on May 2, 2025; board ratified the ratio.
Outstanding shares will reduce from about 23.3M to approximately 833,620.
No fractional shares issued; fractional shares rounded up to nearest whole share.
Effective date to be announced at least two business days prior to implementation.
Split designed to meet Nasdaq minimum bid price requirement for continued listing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.